Equities research analysts expect that NuVasive, Inc. (NASDAQ:NUVA) will post earnings per share of $0.56 for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for NuVasive’s earnings, with the lowest EPS estimate coming in at $0.50 and the highest estimate coming in at $0.66. NuVasive reported earnings of $0.58 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 3.4%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, July 30th.

On average, analysts expect that NuVasive will report full year earnings of $2.28 per share for the current financial year, with EPS estimates ranging from $2.24 to $2.32. For the next year, analysts anticipate that the firm will report earnings of $2.54 per share, with EPS estimates ranging from $2.49 to $2.60. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow NuVasive.

NuVasive (NASDAQ:NUVA) last announced its earnings results on Wednesday, May 1st. The medical device company reported $0.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.12. NuVasive had a return on equity of 15.16% and a net margin of 4.39%. The business had revenue of $274.78 million for the quarter, compared to analysts’ expectations of $269.22 million. During the same period in the prior year, the business posted $0.39 earnings per share. The firm’s revenue was up 5.5% on a year-over-year basis.

A number of equities analysts have issued reports on the company. BidaskClub upgraded NuVasive from a “hold” rating to a “buy” rating in a report on Wednesday, May 8th. ValuEngine upgraded NuVasive from a “hold” rating to a “buy” rating in a report on Tuesday, May 7th. Zacks Investment Research cut NuVasive from a “hold” rating to a “sell” rating in a report on Monday, February 25th. Cantor Fitzgerald restated a “hold” rating and set a $50.00 price target on shares of NuVasive in a report on Monday, February 11th. Finally, Jefferies Financial Group cut NuVasive from a “buy” rating to a “hold” rating and set a $60.00 price target on the stock. in a report on Tuesday, February 12th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $67.43.

In other news, President Matthew Link sold 10,100 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $62.00, for a total transaction of $626,200.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.97% of the stock is owned by corporate insiders.

Several large investors have recently modified their holdings of NUVA. Enlightenment Research LLC acquired a new position in shares of NuVasive during the fourth quarter worth approximately $25,000. Royce & Associates LP acquired a new position in shares of NuVasive during the fourth quarter worth approximately $25,000. Bessemer Group Inc. acquired a new position in shares of NuVasive during the fourth quarter worth approximately $50,000. Rockefeller Capital Management L.P. raised its position in shares of NuVasive by 251.2% during the first quarter. Rockefeller Capital Management L.P. now owns 2,002 shares of the medical device company’s stock worth $114,000 after purchasing an additional 1,432 shares during the period. Finally, Knott David M acquired a new position in shares of NuVasive during the first quarter worth approximately $114,000.

Shares of NUVA stock opened at $61.04 on Friday. NuVasive has a one year low of $43.51 and a one year high of $72.41. The company has a market capitalization of $3.23 billion, a P/E ratio of 27.37, a P/E/G ratio of 2.29 and a beta of 1.21. The company has a current ratio of 3.75, a quick ratio of 1.96 and a debt-to-equity ratio of 0.80.

About NuVasive

NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Featured Story: Using the New Google Finance Tool

Get a free copy of the Zacks research report on NuVasive (NUVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.